What is Generate Biomedicines, Inc. 's cash & equivalents?

Generate Biomedicines, Inc. (GENB) reported cash & equivalents of $160.58M in Q1 2026.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Generate Biomedicines, Inc. GENB Cash & Equivalents

Cash & Equivalents at other companies

MYR GroupMYRG

$163.19M+1,398%

RepligenRGEN

$582.65M-16.4%

NNN REITNNN

$4.57M-10.3%

Piper SandlerPIPR

$344.43M+173%

Sensata TechnologiesST

$635.1M+8.0%

AppFolioAPPF

$147.66M+158%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's cash & equivalents?: Generate Biomedicines, Inc. (GENB) reported cash & equivalents of $160.58M in Q1 2026.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.